Log In
Print
BCIQ
Print
Print this Print this
 

MVA-HCV (TG4040)

  Manage Alerts
Collapse Summary General Information
Company Transgene S.A.
DescriptionRecombinant modified vaccinia Ankara (MVA) virus vector containing nucleotide sequences encoding the non-structural immunogenic NS3, NS4 and NS5B proteins of HCV
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection; Treat HCV genotype 1 infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today